Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Crown Bioscience Enter Into a Business Collaboration with Xstrahl Ltd

Published: Tuesday, October 15, 2013
Last Updated: Tuesday, October 15, 2013
Bookmark and Share
Development of radiation models of cancer will enable the discovery of more effective oncology therapies.

Crown Bioscience, Inc. has announced that it has entered into a collaboration with Xstrahl Ltd, a leading designer and manufacturer of X-Ray solutions for radiation biology research.

As part of the agreement, CrownBio will be implementing the SARRP research platform supplied by Xstrahl, based on Image Guided Micro-Irradiation (IGMI™) techniques at its PRECOS facility in Nottingham, UK.

As a result of the partnership, CrownBio will be at the forefront of providing contract research oncology models that provide an irradiation service based on targeted beam radiation therapy, to more closely mimic the clinical situation for patients in the preclinical setting to help improve potential cancer treatment regimens.

CrownBio is the largest supplier of oncology services, with a global footprint spanning three major continents in North America, Europe and Asia Pacific.

Via its collaboration with Xstrahl, the company is now able to offer its customers computerized tomography (CT) imaging with precise radiation delivery.

High resolution imaging enables researchers to pinpoint an exact clinical target and deliver a precise radiation dose to in vivo and in vitro models. The platform provides the ability to perform combination studies in patient derived xenograft (PDX) and cell line derived xenograft (CDX) models as well as in vitro, in addition to irradiated subjects for haematological or more fastidious models.

Jean-Pierre Wery, President of CrownBio comments, “The partnership represents CrownBio’s commitment to providing its pharmaceutical and biopharmaceutical customers with specialized techniques and services. Radiation therapy is part of the treatment regimen for the majority of cancer patients worldwide. Therefore providing preclinical models which more closely reflect a patient’s condition should be a potential option for validating the efficacy of novel therapies and potential compounds that make tumor cells more sensitive to radiation therapy (radiosensitizers) for the treatment of cancer. The use of the IGMI technique in conjunction with our commercial models will provide a unique portfolio of models which more closely mimic the treatment regimen in the clinic, but in the preclinical setting.”

CrownBio has unique clinically relevant models, which reflect the patient situation for each aspect of cancer progression, encompassing pre-cancerous lesions, primary tumors and metastasis.

Jean-Pierre Wery continues, “We are delighted to partner with Xstrahl in order to further develop unique cutting-edge models that represent patients who have undergone radiation therapy. Conventional chemotherapy has been, for many years, the prevalent type of anti-cancer treatment. However its broad-based mechanisms (e.g. DNA alkylating agents) usually lead to severe systemic side effects and it is becoming increasingly important to consider alternatives to chemotherapy, such as radiation.”

The SARRP platform is designed to close the gap between current clinical techniques and radiation biology/radiotherapy.

The platform enables researchers to confidently assess the efficacy and efficiency of current treatment regimes and provide new data to the medical community that can help to shape the future of radiation protocols and concurrent therapies.

Adrian Treverton - COO at Xstrahl Life Sciences said today, “This unique partnership with CrownBio will enable Xstrahl to enhance our understanding of unique models of radiation and apply this knowledge to the wider oncology drug discovery community. We want to transform the way researchers and clinicians conduct radiation research as well as providing the most advanced platforms for validating the efficacy of novel radiation therapies for cancer and research into normal tissue toxicity. Our expertise in targeted radiotherapy provides a perfect complement to CrownBio’s existing imaging services in order to enhance radiation oncology.”

Preclinical models in radiation oncology are essential tools for cancer research and therapeutics. CrownBio is looking to develop models that can be used to test radiation therapy, including in vitro as well as in vivo orthotopic xenograft models which can ultimately be used to develop more effective cancer therapies.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Crown Bioscience Strengthens Immuno-Oncology Capabilities
Company has announced that it has developed and validated a unique set of models for immuno-oncology called HuGEMM™.
Friday, April 15, 2016
Crown Bioscience Expands Cardiovascular and Metabolic Disease Capabilities
Company has announced Zhen Pang as scientific director.
Thursday, October 15, 2015
Crown Bioscience Brings Top Scientists Together
Experts to discuss best approaches to advance translational oncology.
Saturday, October 03, 2015
Crown Bioscience Strengthens Pre-Clinical Leadership Team with Senior Appointment
The company has appointed Laurie Heilmann as senior vice president.
Friday, July 03, 2015
Crown Bioscience Expands its Partnership with The National Resource Center for Mutant Mice
The expanded collaboration will focus on developing immuno-oncology mouse models and other disease-specific experimental models supporting translational medical research.
Friday, July 03, 2015
Crown Bioscience Acquires Molecular Response’s PDX Business
Company is acquiring all of Molecular Response’s existing PDX models.
Friday, February 13, 2015
Crown Bioscience Expands Operations and Re-Brands UK Site
Existing facility will become centre of excellence for hormonal oncology and step up European operations.
Friday, January 09, 2015
Crown Bioscience Announces U.S. Expansion
New service center will allow the expansion of new immunotherapy experimental platforms to advance translational medical research and the treatment of cancers.
Saturday, October 25, 2014
Crown Bioscience President Honored in PharmaVOICE 100
Dr Jean-Pierre Wery is recognized for pioneering work in translational medicine, improving the efficiency of drug discovery and development.
Friday, August 01, 2014
Crown Reveals Strategy for Combined Drug-IR Therapy to Overcome Resistance
Novel strategies for combining drug therapy with irradiation to deliver new hope for overcoming resistance in the clinic.
Saturday, June 21, 2014
Crown Bioscience to Showcase Progression in Human Surrogate Trials
HuTrialTM demonstrates commitment to furthering preclinical understanding in order to improve personal care and increase patient recovery rates.
Wednesday, May 21, 2014
Crown Bioscience Receives $26.55M Series D Funding
Investment will fund rapid expansion in translational platform technologies for oncology and metabolic diseases.
Monday, May 12, 2014
Crown Bioscience Announces Research Collaboration with the NRCMM
New collaboration aims to develop disease-specific experimental models for translational medical research.
Saturday, May 10, 2014
Crown Bioscience Enters Strategic Partnership with SNBL
Agreement’s initial focus is for SNBL to promote Crown services to its Japanese client base.
Friday, April 25, 2014
Crown Bioscience Passes 1000 Model Mark in PDX Collection for Oncology Drug Discovery
Size of collection allows for more informed preclinical decision making on prospective drug candidates.
Wednesday, April 23, 2014
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Connectome Map More Than Doubles Human Cortex’s Known Regions
Researchers at NIH have developed software that automatically detects the “fingerprint” of each of these areas in an individual’s brain scans.
Discovered Through ‘Big Data’ Analysis
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
Human Stem Cells to Rapidly Generate Bone, Heart Muscle
A new study shows that combining positive and negative signals can quickly and efficiently steer stem cells down complex developmental pathways to become specialized tissues that could be used in the clinic.
New Mechanism of Tuberculosis Infection
Researchers at UTSW Medical Center have identified a new way that tuberculosis bacteria get into the body, revealing a potential therapeutic angle to explore.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Eliminating Doubt in Criminal Investigations
New ASU certificate to help curb error, misunderstanding in the quest for justice.
Determination of 13 Organic Toxicants in Human Blood
Researchers have utilised liquid-liquid extraction coupling HPLC-MS/MS to identify and quantify organic toxicants in human blood.
A Novel Cell Culture Model For Forensic Biology Experiments
Researchers have developed a new cell culture model which provides an efficient research tool in forensic biology.
Rhino DNA Bank Aids Anti-Poaching Fight
At the University of Pretoria's Veterinary Genetics Laboratory (VGL) at Onderstepoort, Dr Cindy Harper and her team have developed a ground-breaking technique to collect and catalogue DNA from rhinos and rhino horns.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!